Phase 2 N=20 Randomized Triple-blind Treatment

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Bottom Line

View on ClinicalTrials.gov: NCT01150461 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2013

Primary outcome: Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic myocardium — p=0.02

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: losartan (Drug); placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Massachusetts General Hospital
Primary completion: Jul 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging.	-23; 31	0.02 sig
SECONDARY Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging.	-5; 5	0.06

Summary

The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle scarring.

Eligibility Criteria

Inclusion Criteria

Patients with hypertrophic cardiomyopathy
Left ventricular outflow tract (LVOT) gradient less than 30 mm Hg at rest
Age 18 years or older

Exclusion Criteria

Contraindication to losartan
Already taking losartan
Contraindication to MRI
Hemodynamic instability

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01150461). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.